SIRPA and neoplasm: Next-generation CD47 blockade has resulted in bispecific antibody platforms that can also target CD19 or CD20 in a mouse lymphoma model[80-82], CD33 or CD123 in AML[83-85], CD40 in colon carcinoma[86], tumor-associated antigens such as mesothelin[87] and VEGFR1[60] in non-small cell lung cancer, and even dual blockade of CD47 and SIRPα[88,89] or SIRPα and PD-L1[90]; however, trials in humans have yet to be conducted.